Entera Bio Stock Forum

$Opko Health (OPK.US)$ $Entera Bio (ENTX.US)$ Reuters· 1 min
Entera Bio and OPKO Health Provide Update on Pk/Pd Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

$Entera Bio (ENTX.US)$
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
Entera Bio (NASDAQ: ENTX) and OPKO Health, Inc. (NASDAQ: OPK) have announced positive results from their collaborative research on an oral oxyntomodulin (OXM) peptide tablet for obesity and metabolic disorders. The study, combining OPKO's proprietary long-acting OXM analog with Entera's N-Tab™ technology, aims to ...

$Annovis Bio (ANVS.US)$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...

$Entera Bio (ENTX.US)$ Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
1 MINUTE AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE

$Entera Bio (ENTX.US)$ Entera Bio Receives Extension From Nasdaq to Regain Compliance With Minimum Bid Price Rule

$Entera Bio (ENTX.US)$ Lets do the house keeping first! Have until 12/26/23 For trade over dollar 30 days to regain compliance! NOT a chance. So R/S may happen? But they could also get 1 more 180 day extension? Waiting to see?
Now to the WATCHING REMINDER! And i will just give you the company’s words for this!  PAY ATTENTION TO LAST SENTENCE !  ((((((    EB612: First Oral PTH(1-34) Peptide Replacement Therapy Tablets for Hypoparathyroidism
EB612, is the first oral formu...

$Entera Bio (ENTX.US)$  
EB613: First Oral PTH(1-34) Daily Osteoanabolic Tablets for Osteoporosis
EB613 (oral PTH (1-34), teriparatide), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for osteoporosis. Entera is prepared to initiate a pivotal phase 3 study in post-menopausal women with high-risk osteoporosis and no prior fracture. Entera successfully completed a phase 2, 6-month, 161-patient, placebo-con...

$Entera Bio (ENTX.US)$ Hoping to see news of recent submission of its qualification plan to the FDA? hopefully a answer will be out before EOY?